The U.S. Food and Drug Administration (FDA) has issued a proposed rule to modernize and clarify drug establishment registration and drug listing requirements for domestic and foreign establishments engaged in the manufacture, preparation, propagation, compounding, or processing of drugs intended for commercial distribution in the United States.
The proposal updates existing regulations to align with statutory changes enacted over the past several years, including provisions from the PREVENT Pandemics Act, while also addressing changes in today’s pharmaceutical manufacturing environment.
Proposed Rule Reflects Changes to FDA Registration Requirements
The proposed rule would update FDA regulations to reflect current statutory requirements while clarifying registration and drug listing responsibilities for a variety of regulated entities.
Among the proposed changes are new requirements for distributed manufacturing arrangements, where multiple establishments participate in manufacturing a drug product. The proposal also clarifies responsibilities for manufacturers, repackagers, relabelers, salvagers, and other businesses involved in the commercial distribution of drugs.
According to the FDA, these updates are intended to improve the accuracy of registration and listing information and strengthen oversight of the pharmaceutical supply chain.
Potential Impact on Pharmaceutical Importers
Although the proposal is directed primarily at FDA-regulated drug establishments, companies that import pharmaceutical products should review the proposed changes carefully. Foreign manufacturers that supply drugs to the U.S. market may need to evaluate whether the updated registration and listing requirements would affect their operations if the rule is finalized.
Accurate establishment registration and drug listing information remain important components of pharmaceutical import compliance and can help reduce the risk of delays during the import process.
Public Comments Due September 11
The FDA is accepting comments on the proposed rule through September 11, 2026. Companies involved in pharmaceutical manufacturing, distribution, or importing should review the proposal to determine whether it may affect their business and consider submitting comments if appropriate.
Alba will continue monitoring this proposed rule and provide updates as additional information becomes available.
Contact the Alba team, out team is ready to assist you.
Want updates like this in your inbox? Subscribe to the newsletter.
